Results of clinical trials with anti-programmed death 1/programmed death ligand 1 inhibitors in lung cancer

Por Viteri, Santiago, González-Cao, María, Barrón, Feliciano, Riso, Aldo, Rosell, Rafael
Publicado no Transl Lung Cancer Res (2015)

Immune checkpoint inhibitors: therapeutic advances in melanoma

Por Márquez-Rodas, Ivan, Cerezuela, Pablo, Soria, Ainara, Berrocal, Alfonso, Riso, Aldo, González-Cao, María, Martín-Algarra, Salvador
Publicado no Ann Transl Med (2015)

Other targeted drugs in melanoma

Por González-Cao, María, Rodón, Jordi, Karachaliou, Niki, Sánchez, Jesús, Santarpia, Mariacarmela, Viteri, Santiago, Pilotto, Sara, Teixidó, Cristina, Riso, Aldo, Rosell, Rafael
Publicado no Ann Transl Med (2015)

Melanoma: oncogenic drivers and the immune system

Por Karachaliou, Niki, Pilotto, Sara, Teixidó, Cristina, Viteri, Santiago, González-Cao, María, Riso, Aldo, Morales-Espinosa, Daniela, Molina, Miguel Angel, Chaib, Imane, Santarpia, Mariacarmela, Richardet, Eduardo, Bria, Emilio, Rosell, Rafael
Publicado no Ann Transl Med (2015)

Fatal gastrointestinal toxicity with ipilimumab after BRAF/MEK inhibitor combination in a melanoma patient achieving pathological complete response

Por Gonzalez-Cao, Maria, Boada, Aram, Teixidó, Cristina, Fernandez-Figueras, María Teresa, Mayo, Clara, Tresserra, Francesc, Bustamante, Jean, Viteri, Santiago, Puertas, Enrique, Santarpia, Mariacarmela, Riso, Aldo, Barron, Feliciano, Karachaliou, Niki, Rosell, Rafael
Publicado no Oncotarget (2016)